Suppr超能文献

亚胺培南/西司他丁钠在儿科领域的基础与临床评价

[Fundamental and clinical evaluation of imipenem/cilastatin sodium in the field of pediatrics].

作者信息

Haruta T, Okura K E, Kuroki S, Yamamoto H, Yamaoka K, Kubo K, Kobayashi Y

出版信息

Jpn J Antibiot. 1986 Jul;39(7):1879-88.

PMID:2945941
Abstract

A combination drug of imipenem (MK-0787), a new carbapenem antibiotic, and cilastatin sodium (MK-0791) at a ratio of 1:1 was used to treat infections in 8 children, and the concentrations of MK-0787 were determined in plasma, urine and pus of 1 patient and in cerebrospinal fluid of another patient. Eight patients, aged 2 months to 12 years (males: 3, females: 5), were treated with MK-0787/MK-0791. They consisted of 3 with urinary tract infections (causative organisms: E. coli, K. oxytoca plus E. faecalis, and unknown), and 1 patient each with pneumonia (H. influenzae), enteritis (Salmonella C1), cellulitis (S. aureus), purulent lymphadenitis (unknown) and purulent meningitis (E. coli). The dose, ranging from 7.4 mg/7.4 mg/kg to 11.8 mg/11.8 mg/kg, 3 or 4 times daily, was administered by a 30-minute or 60-minute intravenous drip infusion for 5 to 11 days. To the patient with purulent meningitis, however, 25.85 mg/25.85 mg/kg on the 1st day and 12.9 mg/12.9 mg/kg from the 2nd day were administered 4 times daily. Clinical responses in urinary tract infections were excellent in 2 and good in 1, and responses in pneumonia, enteritis, cellulitis, purulent lymphadenitis and purulent meningitis were excellent, good, good, excellent and poor, respectively. The efficacy rate in a total of 8 patients was 87.5%. As adverse reactions, a rash was observed in one patient and a convulsion in another. The rash disappeared after discontinuation of the administration of the drug and the convulsion stopped after a reduction of the dosage. As abnormal laboratory findings, slight prolongation of the prothrombin time was observed in 1 patient, but no bleeding tendency was noted. When MK-0787/MK-0791 (500 mg/500 mg, or 8.7 mg/8.7 mg/kg) was given by a 60-minute intravenous drip infusion to a 12-year-old boy with cellulitis, the peak plasma concentration of MK-0787 was 31.4 micrograms/ml occurring at the end of the infusion, and then the concentration decreased to 13.9 micrograms/ml in 0.5 hour, 8.9 micrograms/ml in 1 hour, 2.8 micrograms/ml in 2 hours, 0.63 microgram/ml in 4 hours and 0.14 microgram/ml in 6 hours. The half-life was 0.83 hour. These plasma levels provided concentrations exceeding MIC90's against major infective bacteria for 2 hours. The urinary recovery in the first 7 hours was 75.0%, and the urinary concentration was greater than 100 micrograms/ml for 5 to 7 hours.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

一种新型碳青霉烯类抗生素亚胺培南(MK - 0787)与西司他丁钠(MK - 0791)按1:1比例组成的复方药物用于治疗8例儿童感染,并测定了1例患者血浆、尿液和脓液以及另1例患者脑脊液中的MK - 0787浓度。8例患者年龄在2个月至12岁之间(男3例,女5例),接受MK - 0787/MK - 0791治疗。其中3例为尿路感染(致病菌分别为大肠杆菌、产酸克雷伯菌加粪肠球菌以及不明菌),1例肺炎(流感嗜血杆菌),1例肠炎(沙门菌C1),1例蜂窝织炎(金黄色葡萄球菌),1例化脓性淋巴结炎(不明菌),1例化脓性脑膜炎(大肠杆菌)。剂量为7.4毫克/7.4毫克/千克至11.8毫克/11.8毫克/千克,每日3或4次,通过30分钟或60分钟静脉滴注给药5至11天。然而,对于化脓性脑膜炎患者,第1天给予25.85毫克/25.85毫克/千克,第2天起给予12.9毫克/12.9毫克/千克,每日4次。尿路感染的临床反应2例为优,1例为良;肺炎、肠炎、蜂窝织炎、化脓性淋巴结炎和化脓性脑膜炎的反应分别为优、良、良、优和差。8例患者的总有效率为87.5%。不良反应方面,1例患者出现皮疹,另1例出现惊厥。停药后皮疹消失,减量后惊厥停止。实验室检查异常方面,1例患者凝血酶原时间稍有延长,但未发现出血倾向。当对1例患有蜂窝织炎的12岁男孩以60分钟静脉滴注方式给予MK - 0787/MK - 0791(500毫克/500毫克,即8.7毫克/8.7毫克/千克)时,MK - 0787的血浆峰浓度在滴注结束时为31.4微克/毫升,然后在0.5小时降至13.9微克/毫升,1小时降至8.9微克/毫升,2小时降至2.8微克/毫升,4小时降至0.63微克/毫升,6小时降至0.14微克/毫升。半衰期为0.83小时。这些血浆水平使药物浓度超过主要感染细菌的MIC90达2小时。前7小时尿液回收率为75.0%,尿液浓度在5至7小时大于100微克/毫升。(摘要截短至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验